TriLink BioTechnologies Overview
- Year Founded
-
1996
- Status
-
Acquired/Merged
- Employees
-
303
- Latest Deal Type
-
Accelerator/Inc
- Financing Rounds
-
4
- Investments
-
3
TriLink BioTechnologies General Information
Description
Developer of modified nucleic acids intended for the synthesis of nucleic acids, NTPs (Nucleotide Triphosphates), and mRNA (messenger RNA) capping analogs. The company offers custom oligonucleotides, nucleoside triphosphates, and synthesis reagents for research and diagnostic laboratories, as well as offers radio-labeling services, custom chemistry, and contract research services for oligos and small molecules, allowing its clients to move from early research into clinical trials.
Contact Information
Website
www.trilinkbiotech.com(Operating Subsidiary)
Corporate Office
- 10770 Wateridge Circle
- Suite 200
- San Diego, CA 92121
- United States
Corporate Office
- 10770 Wateridge Circle
- Suite 200
- San Diego, CA 92121
- United States
TriLink BioTechnologies Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
TriLink BioTechnologies Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
TriLink BioTechnologies Patents
TriLink BioTechnologies Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026236585-A2 | Modified rna for increasing protein expression | Pending | 09-May-2025 | ||
| EP-4837033-A2 | Modified rna for increasing protein expression | Pending | 03-Jan-2025 | ||
| WO-2026029973-A1 | Cap analogs and methods of use thereof | Pending | 30-Jul-2024 | ||
| WO-2026010855-A1 | Modified rna for increasing protein expression | Pending | 02-Jul-2024 | ||
| WO-2025184082-A1 | Novel cap analogs and methods of use thereof | Pending | 26-Feb-2024 | C07H21/02 |
TriLink BioTechnologies Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
TriLink BioTechnologies Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
TriLink BioTechnologies Investments & Acquisitions (3)
TriLink BioTechnologies’s most recent deal was a Merger/Acquisition with MyChem for . The deal was made on 28-Jan-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| MyChem | 28-Jan-2022 | Merger/Acquisition | Specialty Chemicals | ||
| Solulink | 01-Feb-2017 | Merger/Acquisition | Biotechnology | ||
| Solulink | 28-Feb-2008 | Early Stage VC | Biotechnology |
TriLink BioTechnologies Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| MyChem | San Diego, CA | 2007 |
TriLink BioTechnologies FAQs
-
When was TriLink BioTechnologies founded?
TriLink BioTechnologies was founded in 1996.
-
Where is TriLink BioTechnologies headquartered?
TriLink BioTechnologies is headquartered in San Diego, CA.
-
What is the size of TriLink BioTechnologies?
TriLink BioTechnologies has 303 total employees.
-
What industry is TriLink BioTechnologies in?
TriLink BioTechnologies’s primary industry is Other Pharmaceuticals and Biotechnology.
-
Is TriLink BioTechnologies a private or public company?
TriLink BioTechnologies is a Private company.
-
What is TriLink BioTechnologies’s current revenue?
The current revenue for TriLink BioTechnologies is .
-
Who are TriLink BioTechnologies’s investors?
Small Business Innovation Research and Small Business Technology Transfer Programs has invested in TriLink BioTechnologies.
-
Who acquired TriLink BioTechnologies?
TriLink BioTechnologies was acquired by Maravai LifeSciences.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
